Intas Pharma Ltd. Walk - In Drives On 21st Oct. 2018 For Multiple post.
About Intas Pharmaceutical:-
Intas is the leading, genetically integrated global drug production formulation, production and marketing company with the headquarters in India.
Successful and sustained growth of intas is in the clinical implementation of successful and strategic movements in the field of manufacturing, R & D, biotechnology and global action for three decades. By March 31, 2018, Intas has registered 20% CAGR of $ 1.7 billion in the last 5 years. Intas is currently 11th in the Indian pharma market with 2.9% market share.
Enjoy leadership positions in long-term treatments, such as intrusion neurology, psychotherapy, cardiovascular, diabetes, oncology, urology, nephrology, rheumatology and gynecology, infertility, gastroenterology, pen management, and healthy presence in other major therapeutic segments.
In addition to domestic reputation, in the more than 80 countries around the world, intas is also present in markets such as North America, Europe, Central and Latin America, Africa, Australia, New Zealand, Asia-Pacific, with strong sales, marketing and distribution infrastructure. As the country of CIS and MENA The Intussa Global Policy includes alliances with leading global pharma companies for direct product distribution for the development and distribution of products. The company is famous for a range of products from oncology and the therapeutic departments based on the EU and other hospitals in the US. After the crucial acquisition of Teve's assets, Intas became the leading player in the UK's generic market.
Intas has firmly committed to the Biology Business Unit in order to create R & D, manufacturing and marketing capabilities for biotech portfolio. This is the first company to launch the first petitated acquisition technology-based distribution system in the EU (Philagratum and Peg-Philgustim) and Bioscianer market.
Intas is the fastest growing Indian company with biosimals at the 13th position of BioSimilar. Including DocketClex and Paclitaxel. In today's world, Intas continues to research and develop a range of acute illnesses such as cancer, rheumatism, autoimmunity, nephrology, ophthalmology and plasma-generated therapies.
Intas 'success and development intas' have extensive R & D capabilities, its production capacity and its impact directly on its people. Every year, the company spends about 6-7% of its revenues in R & D. In addition to creating a regular portfolio of generic products, Intel 'R & D' focuses on developing new technology based technology and piping pipelines, and in the last 8 years, has invested 125 million dollars to develop and enhance biozimmillar capacity.
Intas operates fourteen formulation facilities, seven of which are located in India, and in the rest of the UK and Mexico. Top global regulators like USFDA, EMA, MHRA, TGA etc. have approved two major facilities. This is the first company in India which has been approved by the European Health Authority.
